rs201591901
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 5P and 2B. PM1PM2PP3BP4_Moderate
The NM_000492.4(CFTR):c.3289C>T(p.Arg1097Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000614 in 1,613,452 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000092 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000058 ( 1 hom. )
Consequence
CFTR
NM_000492.4 missense
NM_000492.4 missense
Scores
15
2
2
Clinical Significance
Conservation
PhyloP100: 4.76
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PM1
In a helix (size 50) in uniprot entity CFTR_HUMAN there are 11 pathogenic changes around while only 0 benign (100%) in NM_000492.4
PM2
Very rare variant in population databases, with high coverage;
PP3
Multiple lines of computational evidence support a deleterious effect 10: AlphaMissense, BayesDel_noAF, Cadd, Dann, Eigen, M_CAP, MutationAssessor, PrimateAI, PROVEAN, REVEL [when max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]
BP4
Computational evidence support a benign effect (MetaRNN=0.24358985).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3289C>T | p.Arg1097Cys | missense_variant | 20/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000856 AC: 13AN: 151954Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
13
AN:
151954
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000267 AC: 67AN: 251114Hom.: 0 AF XY: 0.000251 AC XY: 34AN XY: 135700
GnomAD3 exomes
AF:
AC:
67
AN:
251114
Hom.:
AF XY:
AC XY:
34
AN XY:
135700
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000582 AC: 85AN: 1461380Hom.: 1 Cov.: 31 AF XY: 0.0000619 AC XY: 45AN XY: 727008
GnomAD4 exome
AF:
AC:
85
AN:
1461380
Hom.:
Cov.:
31
AF XY:
AC XY:
45
AN XY:
727008
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000921 AC: 14AN: 152072Hom.: 0 Cov.: 31 AF XY: 0.000121 AC XY: 9AN XY: 74328
GnomAD4 genome
AF:
AC:
14
AN:
152072
Hom.:
Cov.:
31
AF XY:
AC XY:
9
AN XY:
74328
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
22
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Cystic fibrosis Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 07, 2023 | The p.R1097C variant (also known as c.3289C>T), located in coding exon 20 of the CFTR gene, results from a C to T substitution at nucleotide position 3289. The arginine at codon 1097 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was reported in a Chinese bronchiectasis cohort in one individual who had an additional CFTR variant detected (phase not described) and a SCCN1B variant detected, and it was also reported in one control individual (Guan WJ et al. J Thorac Dis, 2018 May;10:2618-2630). This variant was also detected in a recurrent intrahepatic cholestasis case who had an additional CFTR variant detected, where phase was not described (Chen HL et al. J. Pediatr., 2019 02;205:153-159.e6). Finally, this variant was described in a nonobstructive azoospermia cohort; however, clinical details were not provided (Liu X et al. Med. Sci. Monit., 2019 Aug;25:5801-5812). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | May 10, 2018 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 14, 2023 | Observed in individuals with bronchiectasis, congenital absence of the vas deferens, or recurrent intrahepatic cholestasis, some of whom also harbored additional CFTR variants, but segregation data was absent for these individuals (Guan et al., 2018; Luo et al., 2021; Chen et al., 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29997923, 30366773, 35313924, 31377750, 32734384, 32777524) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 29, 2018 | - - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 17, 2024 | The CFTR c.3289C>T variant is predicted to result in the amino acid substitution p.Arg1097Cys. This variant was reported in individuals with recurrent intrahepatic cholestasis and congenital absence of the vas deferens (Chen et al. 2019. PubMed ID: 30366773; Luo et al. 2020. PubMed ID: 32777524). This variant is reported in 0.37% of alleles in individuals of East Asian descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;.;.;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;.;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;.;.;D;.
REVEL
Pathogenic
Sift
Pathogenic
D;.;.;D;.
Sift4G
Pathogenic
D;.;.;D;.
Polyphen
D;.;.;.;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at